IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
Rhea-AI Summary
IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for August 11, 2025, at 8:30 AM ET to reveal topline results from its pivotal Phase 3 trial (IOB-013/KN-D18). The trial evaluates Cylembio, an investigational immune-modulatory cancer vaccine, in combination with KEYTRUDA® versus KEYTRUDA® alone for first-line treatment of advanced melanoma.
The study focuses on patients with unresectable or metastatic melanoma, with management hosting a live discussion of the results. A replay will be available on the company's website after the event.
Positive
- None.
Negative
- None.
News Market Reaction 112 Alerts
On the day this news was published, IOBT declined 41.99%, reflecting a significant negative market reaction. Argus tracked a peak move of +45.5% during that session. Argus tracked a trough of -56.3% from its starting point during tracking. Our momentum scanner triggered 112 alerts that day, indicating very high trading interest and price volatility. This price movement removed approximately $97M from the company's valuation, bringing the market cap to $134M at that time. Trading volume was exceptionally heavy at 138.7x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma.
Webcast and Conference Call Information
The IO Biotech management team will host a webcast/conference call on Monday, August 11, 2025, at 8:30 a.m. ET to discuss the topline results from the Phase 3 trial of Cylembio. Those who would like to participate may access the live webcast here or register in advance for the teleconference here . A replay of the webcast will be available on the IO Biotech website following the live event.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Contacts:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Edelman
917-498-1967
julie.funesti@edelman.com
FAQ
When will IO Biotech (IOBT) announce Phase 3 trial results for Cylembio?
What is the purpose of IO Biotech's Phase 3 trial for Cylembio?
What type of drug is IO Biotech's Cylembio?
How can investors access IO Biotech's Phase 3 results presentation?
What is the trial identification number for IO Biotech's Phase 3 Cylembio study?
